Cell Signaling Technology

Product Pathways - Lymphocyte Signaling

IDO (D5J4E™) Rabbit mAb (PE Conjugate) #10312

Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype
F 1:50 Human, Endogenous Rabbit IgG

Species cross-reactivity is determined by western blot.

Applications Key: F=Flow Cytometry,

Specificity / Sensitivity

IDO (D5J4E) Rabbit mAb (PE Conjugate) recognizes endogenous levels of total IDO protein. Some nonspecific staining of normal breast epithelium has been observed.

Source / Purification

Monoclonal antibody is produced by immunizing animals with recombinant human IDO protein.


This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometry analysis in human cells. This antibody is expected to exhibit the same species cross-reactivity as the unconjugated IDO (D5J4E) Rabbit mAb #86630.

Flow Cytometry

Flow Cytometry

Flow cytometric analysis of HeLa cells, untreated (blue) or treated with Human Interferon-γ (hIFN-γ) #8901 (10 ng/ml, 16 hr; green) using IDO (D5J4E) Rabbit mAb (PE Conjugate).


INDO/IDO1/indoleamine 2,3-dioxygenase (IDO) is an IFN-γ-inducible enzyme that catalyzes the rate-limiting step of tryptophan degradation (1). IDO is upregulated in many tumors and in dendritic cells in tumor-draining lymph nodes. Elevated tryptophan catabolism in these cells leads to tryptophan starvation of T cells, limiting T cell proliferation and activation (2). Therefore, IDO is considered an immunosuppresive molecule, and research studies have shown that upregulation of IDO is a mechanism of cancer immune evasion (3). The gastrointestinal stromal tumor drug, imatinib, was found to act, in part, by reducing IDO expression, resulting in increased CD8+ T cell activation and induction of apoptosis in regulatory T cells (4). In addition to its enzymatic activity, IDO was recently shown to have signaling capability through an immunoreceptor tyrosine-based inhibitory motif (ITIM) that is phosphorylated by Fyn in response to TGF-β. This leads to recruitment of SHP-1 and activation of the noncanonical NF-κB pathway (5).

  1. Yasui, H. et al. (1986) Proc Natl Acad Sci U S A 83, 6622-6.
  2. Mellor, A.L. et al. (2003) Adv Exp Med Biol 527, 27-35.
  3. Prendergast, G.C. (2008) Oncogene 27, 3889-900.
  4. Balachandran, V.P. et al. (2011) Nat Med 17, 1094-100.
  5. Pallotta, M.T. et al. (2011) Nat Immunol 12, 870-8.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!


Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0


我要参与评论 :